Sumitomo Dainippon Pharma Co., Ltd.
49 articles about Sumitomo Dainippon Pharma Co., Ltd.
Sunovion Pharmaceuticals announced it submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for apomorphine sublingual film to treat OFF episodes in Parkinson’s disease (PD).
Poxel and Sumitomo Dainippon Pharma Announce Initiation of Phase III Program for Imeglimin, an Investigational Therapeutic Agent for Type 2 Diabetes, in Japan
In December 2017, the first patient was included in the TIMES 1 trial, a multicenter, double-blind, placebo-controlled, randomized, monotherapy study in over 200 Japanese patients with type 2 diabetes.
The two companies will jointly develop Imeglimin for the treatment of type 2 diabetes in Japan.
Sharp Edge Labs Enters Into Drug Discovery Collaboration With Sumitomo Dainippon Pharma
295 Sumitomo Dainippon Pharma Employees Take Early Retirement
GHIT Fund Welcomes Ten New Partnerships With FUJIFILM, Otsuka, GlaxoSmithKline, Johnson & Johnson, Kyowa Hakko Kirin, Merck & Co., Mitsubishi Tanabe, Nipro Corporation, Sumitomo Dainippon Pharma Co., Ltd. And Salesforce.Com
Elixirgen Announces License Agreement With Sumitomo Dainippon Pharma Co., Ltd.
ex scientia Ltd. Reaches First Delivery Milestone In Collaboration With Sumitomo Dainippon Pharma Co., Ltd.
Sumitomo Dainippon Pharma Co., Ltd. , Takeda Terminate Latuda Agreement